Scarica l'app Stockscreener
1.36
0.74%
0.01
Dopo l'orario di chiusura:
1.36
Precedente Chiudi:
$1.35
Aprire:
$1.35
Volume 24 ore:
162.01K
Relative Volume:
0.78
Capitalizzazione di mercato:
$51.20M
Reddito:
$25.21M
Utile/perdita netta:
$-87.87M
Rapporto P/E:
-0.577
EPS:
-2.357
Flusso di cassa netto:
$-89.47M
1 W Prestazione:
+8.80%
1M Prestazione:
-9.33%
6M Prestazione:
-19.53%
1 anno Prestazione:
-16.05%
Intervallo 1D:
$1.28
$1.37
Intervallo di 1 settimana:
$1.25
$1.375
Portata 52W:
$1.24
$3.95
Metagenomi Therapeutics Inc Stock (MGX) Company Profile
Nome
Metagenomi Therapeutics Inc
Settore
Industria
Telefono
(510) 871-4880
Indirizzo
5959 HORTON STREET, EMERYVILLE
Compare MGX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MGX
Metagenomi Therapeutics Inc
|
1.36 | 50.82M | 25.21M | -87.87M | -89.47M | -2.357 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Metagenomi Therapeutics Inc Stock (MGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-07 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-03-05 | Iniziato | BMO Capital Markets | Outperform |
| 2024-03-05 | Iniziato | Chardan Capital Markets | Buy |
| 2024-03-05 | Iniziato | JP Morgan | Overweight |
| 2024-03-05 | Iniziato | Jefferies | Buy |
| 2024-03-05 | Iniziato | TD Cowen | Outperform |
| 2024-03-05 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Metagenomi Therapeutics Inc Borsa (MGX) Ultime notizie
MGX Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineQuarterly Earnings Report - Newser
MGX Q1 2026 Earnings: Missed Expectations as Pre-Revenue Biotech Advances Gene Editing PipelineEarnings Cycle Outlook - Newser
PRN_FinancialWrapper - FinancialContent
Number of shareholders of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Metagenomi Therapeutics (MGX) price target decreased by 10.71% to 8.50 - MSN
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
Analysts Have Lowered Expectations For Metagenomi Therapeutics, Inc. (NASDAQ:MGX) After Its Latest Results - simplywall.st
Metagenomi Therapeutics (MGX) reports Q1 loss, misses revenue estimates - MSN
Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
MSN Money - MSN
Metagenomi Highlights Q1 Progress on MGX-001 Gene Therapy - TipRanks
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results - The Manila Times
Metagenomi Therapeutics: Q1 Earnings Snapshot - KVUE
Metagenomi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Metagenomi Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Metagenomi (NASDAQ: MGX) details Q1 2026 loss, cash runway and MGX-001 IND plans - Stock Titan
Metagenomi gene edit for hemophilia A targets 2027 human trials - Stock Titan
MGX Stock Price, Quote & Chart | METAGENOMI THERAPEUTICS INC (NASDAQ:MGX) - ChartMill
Hemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
SEC Form DEF 14A filed by Metagenomi Therapeutics Inc. - Quantisnow
[DEF 14A] Metagenomi Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
MGX Price Today: Metagenomi Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Metagenomi Therapeutics (MGX) Stock: Sentiment Analysis (Weakens) 2026-04-22Large Cap Trends - Xã Thanh Hà
MGX Financials: Income Statement, Balance Sheet & Cash Flow | Metagenomi Therapeutics, Inc - Stock Titan
A smaller gene editor cut Atxn2 protein 64% in mice, Metagenomi says - Stock Titan
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Eastern Progress
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency - The Manila Times
What is the valuation of Metagenomi Therapeutics (MGX) Stock | Price at $1.39, Up 0.72%Expert Market Insights - Newser
[Form 4] Metagenomi Therapeutics, Inc. Insider Trading Activity - Stock Titan
MGX: Metagenomi Therapeutics, Inc.Detailed Earnings Estimates - Zacks Investment Research
Metagenomi Can’t Ax IPO Investor Suit Over Moderna Partnership - Bloomberg Law News
If You Invested $1,000 in Metagenomi Therapeutics, Inc (MGX) - Stock Titan
Metagenomi Therapeutics Fiscal Results: Q4 Loss of $22.5M, Annual Loss $87.9MNews and Statistics - IndexBox
Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Metagenomi Therapeutics: Q4 Earnings Snapshot - kens5.com
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results - Bitget
Metagenomi Therapeutics Q4 Earnings Assessment - Benzinga
MGX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
MGX Technical Analysis & Stock Price Forecast - Intellectia AI
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference - The Manila Times
Metagenomi Therapeutics, Inc. CEO Jian Irish to Speak at 46th Annual TD Cowen Healthcare Conference - Quiver Quantitative
Gene-editing firm Metagenomi CEO in TD Cowen fireside chat - Stock Titan
MGXMetagenomi Therapeutics, Inc Latest Stock News & Market Updates - Stock Titan
Is Metagenomi Therapeutics (NASDAQ:MGX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Head to Head Analysis: Acusphere (OTCMKTS:ACUS) and Metagenomi (NASDAQ:MGX) - Defense World
Xeris Biopharma (NASDAQ:XERS) and Metagenomi (NASDAQ:MGX) Critical Comparison - Defense World
Metagenomi Therapeutics Inc Azioni (MGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):